Songwei Tan

Prof. Dr. Songwei Tan

School of Pharmacy, Huazhong University of Science and Technology, Wuhan, China
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2012 in Biomaterials
Verified
Journal Article
Closed access
ZZZhiping Zhang
Zhiping Zhang
Songwei TanSongwei Tan
Songwei Tan
SFSi-Shen Feng
Si-Shen Feng

1 May 2013 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
YGYuanyuan Guo
Yuanyuan Guo
JLJun Luo
Jun Luo
Songwei TanSongwei Tan
Songwei Tan
BOBen Oketch Otieno
Ben Oketch Otieno
ZZZhiping Zhang
Zhiping Zhang

1 January 2015 in Theranostics
Verified
Journal Article
Open access
Songwei TanSongwei Tan
Songwei Tan
TWTingting Wu
Tingting Wu
DZDan Zhang
Dan Zhang
ZZZhiping Zhang
Zhiping Zhang
Natural cells have been explored as drug carriers for a long period. They have received growing interest as a promising drug delivery system (DDS) until recently along with the development of biology and medical science. The synthetic materials, either organic or inorganic, are found to be with more or less immunogenicity and/or toxicity. The cells and extracellular vesicles (EVs), are endogenous and thought to be much safer and friendlier. Furthermore, in view of their host attributes, they may achieve different biological effects and/or targeting specificity, which can meet the needs of personalized medicine as the next generation of DDS. In this review, we summarized the recent progress in cell or cell membrane-based DDS and their fabrication processes, unique properties and applications, including the whole cells, EVs and cell membrane coated nanoparticles. We expect the continuing development of this cell or cell membrane-based DDS will promote their clinic applications.

22 October 2010 in Advanced Materials
Verified
Journal Article
Closed access
PDF file
DZDan Zhao
Dan Zhao
Songwei TanSongwei Tan
Songwei Tan
DYDaqiang Yuan
Daqiang Yuan
WLWeigang Lu
Weigang Lu
YRYohannes H. Rezenom
Yohannes H. Rezenom
HZHong-Cai Zhou
Hong-Cai Zhou

5 September 2017 in Nano Letters
Verified
Journal Article
Closed access
QSQingle Song
Qingle Song
YYYijia Yin
Yijia Yin
LSLihuan Shang
Lihuan Shang
TWTingting Wu
Tingting Wu
DZDan Zhang
Dan Zhang
ZZZhiping Zhang
Zhiping Zhang

1 January 2017 in Theranostics
Verified
Journal Article
Open access
MKMiao Kong
Miao Kong
JTJiamin Tang
Jiamin Tang
QQQi Qiao
Qi Qiao
TWTingting Wu
Tingting Wu
YQYan Qi
Yan Qi
ZZZhiping Zhang
Zhiping Zhang
There is accumulating evidence that regulating tumor microenvironment plays a vital role in improving antitumor efficiency. Herein, to remodel tumor immune microenvironment and elicit synergistic antitumor effects, lipid-coated biodegradable hollow mesoporous silica nanoparticle (dHMLB) was constructed with co-encapsulation of all-trans retinoic acid (ATRA), doxorubicin (DOX) and interleukin-2 (IL-2) for chemo-immunotherapy. The nanoparticle-mediated combinational therapy provided a benign regulation on tumor microenvironment through activation of tumor infiltrating T lymphocytes and natural killer cells, promotion of cytokines secretion of IFN-γ and IL-12, and down-regulation of immunosuppressive myeloid-derived suppressor cells, cytokine IL-10 and TGF-β. ATRA/DOX/IL-2 co-loaded dHMLB demonstrated significant tumor growth and metastasis inhibition, and also exhibited favorable biodegradability and safety. This nanoplatform has great potential in developing a feasible strategy to remodel tumor immune microenvironment and achieve enhanced antitumor effect.